// App-Quantinova.ai

3545 : Phase II trial of the autophagy inhibitor hydroxychloroquine with FOLFOX and bevacizumab in front line treatment of metastatic colorectal cancer.

Researchers

Presenter

  • Mark H. O'Hara

Principal Investigators

  • Thomas Benjamin Karasic

  • Irina Vasilevskaya

  • Maryann Redlinger

  • Arturo Loaiza-Bonilla

  • Ursina R. Teitelbaum

  • Bruce J. Giantonio

  • Nevena Damjanov

  • Kim Anna Reiss

  • Mark Alan Rosen

  • Daniel F Heitjan

  • Andrea B. Troxel

  • Ravi K. Amaravadi

  • Peter J. O'Dwyer

Medical Centers

  • Abramson Cancer Center, Philadelphia, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxychloroquine

  • Bevacizumab

  • mFOLFOX6

  • Oxaliplatin, 5-fluorouracil and folic acid

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01206530

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved